TKTX Transkaryotic Therapies (MM)

TKT to Present at Two Upcoming Healthcare Conferences CAMBRIDGE, Mass., March 24 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today announced that it will present at two upcoming conferences on Thursday, March 31, 2005: Smith Barney Citigroup's 2005 Healthcare Conference being held March 29-31, 2005 in Washington, D.C. and Lehman Brothers' Eighth Annual Healthcare Conference being held March 30- April 1, 2005 in Miami, Florida. Michael J. Astrue, President and Chief Executive Officer, will present an overview of TKT's business activities and product pipeline at the Citigroup conference on Thursday, March 31, 2005 at 10:20 a.m. Eastern Time. David D. Pendergast, Ph.D., Executive Vice President and Chief Operating Officer will present an overview of TKT's business activities and product pipeline at the Lehman Brothers conference on Thursday, March 31, 2005 at 3:15 p.m. Eastern Time. A live audio webcast of these presentations will be available at http://www.tktx.com/ on TKT's Investor Information website under the Events category. A replay will be available for approximately 30 days after the webcast. About TKT Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused on researching, developing and commercializing treatments for rare diseases caused by protein deficiencies. Within this focus, the company markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is developing treatments for Hunter syndrome and Gaucher disease. In addition to its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin product for anemia related to kidney disease, in the European Union. TKT was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada and South America. Additional information about TKT is available on the company's website at http://www.tktx.com/. Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA. Contact: Justine E. Koenigsberg Senior Director, Corporate Communications (617) 349-0271 http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies, Inc. CONTACT: Justine E. Koenigsberg, Senior Director, Corporate Communications of TKT, +1-617-349-0271 Web site: http://www.tktx.com/ Company News On-Call: http://www.prnewswire.com/comp/120657.html

Copyright